RecruitingNCT07122700

Evaluation of Non-Invasive Tests for Metabolic Liver Disease

Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) Study 2.0 - An FNIH Biomarkers Consortium Study

Sponsor

Foundation for the National Institutes of Health

Enrollment

400 participants

Start Date

May 13, 2025

Study Type

OBSERVATIONAL

Conditions

Cirrhosis, Liver Liver Fibrosis Liver Steatoses NASH Metabolic Associated Fatty Liver Disease Liver Fat Metabolic-Associated Steatotic Liver Disease Liver Inflammation

Summary

The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers to diagnose and stage Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). MASH is characterized by liver inflammation accompanied by simultaneous fat accumulation in the liver.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with cirrhosis, liver, liver fat, and other related conditions. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.